All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib-Reference-Cited by-同舟云学术

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

Published:2012-11-14 Issue:12 Volume:3 Page:1557-1565
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cassuto Ophélie¹²³⁴,Dufies Maeva¹²,Jacquel Arnaud¹²,Robert Guillaume¹²,Ginet Clémence¹²,Dubois Alix¹²,Hamouda Amine¹²,Puissant Alexandre¹²,Luciano Fredéric¹²,Karsenti Jean-Michel³,Legros Laurence³,Cassuto Jill Patrice³,Lenain Pascal⁴,Auberger Patrick¹²³

Affiliation:

1. C3M/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France

2. Equipe Labellisée Ligue Nationale contre le Cancer 2011-2013, Paris, France

3. Service d'Hématologie Clinique et de Transplantation, CHU de Nice, France

4. Centre Henri Becquerel, CLCC, Rouen, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism;Scientific Reports;2023-08-11

2. Association between PAX8AS1 (rs4848320 C > T, rs1110839 G > T, and rs6726151 T > G) and MEG3 (rs7158663) gene polymorphisms and non-Hodgkin lymphoma risk;Nucleosides, Nucleotides & Nucleic Acids;2022-08-08

3. The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach;Frontiers in Cell and Developmental Biology;2021-03-04

4. Recent advances in the combination delivery of drug for leukemia and other cancers;Expert Opinion on Drug Delivery;2020-01-22

5. MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia;YAKUGAKU ZASSHI;2018-12-01